TABLE 2.
Characteristics of patients with pre-existing IP (n=200)
| IPF or non-IPF | |
| IPF | 92 (46.0%) |
| Non-IPF | 108 (54.0%) |
| Non-IPF classification | |
| CHP | 5 (2.5%) |
| COP | 2 (1.0%) |
| DIP | 2 (1.0%) |
| NSIP | 10 (5.0%) |
| CVD-IP | 10 (5.0%) |
| Unclassifiable ILD | 65 (32.5%) |
| Others | 14 (7.0%) |
| HRCT pattern | |
| UIP | 51 (25.5%) |
| Probable UIP | 51 (25.5%) |
| Indeterminate for UIP | 66 (33.0%) |
| Alternative diagnosis | 19 (9.5%) |
| Others | 13 (6.5%) |
| CPFE | |
| Yes | 107 (53.5%) |
| No | 93 (46.5%) |
| Steroids | |
| Yes | 18 (9.0%) |
| No | 182 (91.0%) |
| Antifibrotic drugs | |
| Pirfenidone | 7 (3.5%) |
| Nintedanib | 8 (4.0%) |
| Nonsteroid immunosuppressive drugs | |
| Yes | 3 (1.5%) |
| No | 197 (98.5%) |
| Serum marker of IP | |
| LDH (IU·mL−1) | 221.9±73.6 |
| KL-6 (U·mL−1) | 686.4±467.9 |
| SP-D (ng·mL−1) | 126.9±101.5 |
| Pulmonary function testing | |
| % VC (%) | 93.0±21.1 |
| % FVC (%) | 93.2±20.0 |
| FEV1% (%) | 74.9±10.7 |
| % DLCO (%) | 74.2±25.1 |
IP: interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; CHP: chronic hypersensitivity pneumonia; COP: cryptogenic organising pneumonia; DIP: desquamative interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; CVD: collagen vascular diseases; ILD: interstitial lung disease; UIP: usual interstitial pneumonia; CPFE: combined pulmonary fibrosis and emphysema; LDH: lactate dehydrogenase; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein D; VC: % vital capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide.